The FDA panel aimed to evaluate the safety of antidepressants during pregnancy, especially SSRIs like Prozac and Zoloft. It featured diverse participants, with most expressing skepticism about these medications. Only one panelist defended SSRIs as safe. Critics included a tapering clinic owner and an anti-vaccine advocate, questioning the scientific consensus on antidepressants and their potential link to conditions like autism. This event highlighted the lack of clear guidance for expectant mothers relying on antidepressants, complicating their treatment choices during pregnancy.
The panel, convened to 'challenge or defend current dogma', featured varied views, including those skeptical of antidepressants' effectiveness in pregnancy.
SSRIs, the most commonly prescribed antidepressants like Prozac and Zoloft, were the primary focus of the panel's heated debate.
Among the 10 panelists, only one argued in favor of SSRIs' safety during pregnancy, revealing a significant divide in expert opinion.
Panelists included figures known for controversial views, like an anti-vaccine podcast host and a tapering clinic owner, raising concerns about credibility.
Collection
[
|
...
]